Clinical trial
A Phase 1/2 Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients
NCT05441553 is registered in ClinicalTrials.gov with Shanghai Vitalgen BioPharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients
- Lead sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- July 31, 2022
- Completion date
- January 31, 2025
- Enrollment
- 26 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.